aDivision of Infectious Diseases, Weill Cornell Medicine, New York, NY;
bDivision of Geriatrics and Palliative Medicine, Weill Cornell Medicine, New York, NY;
cDivision of Nephrology and Hypertension, Weill Cornell Medicine, New York, NY;
dCurrently, Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ;
eClinical and Translational Science Center, Weill Cornell Medicine, New York, NY;
fDivision of Endocrinology, Diabetes & Metabolism, Weill Cornell Medicine, New York, NY; and
gCurrently, Department of Psychology, Stony Brook University, Stony Brook, NY.
Correspondence to: Carrie D. Johnston, MD, MS, Division of Infectious Diseases, Weill Cornell Medicine, 525 E. 68th St, Baker Tower, F2331, New York, NY 10065 (e-mail: [email protected]).
Supported by the National Institutes of Health (Grant numbers T32 AI007613 to C.J., K23AG 072960 to C.J., and T32 AG049666 and K99 CA245488 to H.D., National Center for Advancing Translational Sciences UL1TR000457), the Weill Cornell Fund for the Future Award to C.J., the American Psychological Foundation Visionary Grant, and Gilead Sciences.
E.L.S., M.C.R., and Y.-S.Z. have no conflicts of interest. C.D.J is a consultant for TheraTechnologies. K.C.H. receives consulting fees from Faeth Therapeutics, Inc.; is on the review board for PESI, Inc.; and receives personal fees for reviewing professional nutrition education programing for PESI, Inc. The spouse of H.M.D.-V. holds employment at Elanco. The spouse of M.E.C. is a cofounder and shareholder and serves on the Scientific Advisory Board of Proterris, Inc. M.J.G. reports research support to the institution (Weill Cornell) from Gilead Sciences and Regeneron; is a consultant for Enzychem, Regeneron, ReAlta Life Sciences, and Sobi and receives royalties from Springer and UpToDate.
Data presented, in part, at CROI 2020 (Virtual, March 8, 2020).
